 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12...16171819202122232425262728» |
- Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Enrollment closed, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 17, 2012
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Completed --> Active, not recruiting
- docetaxel / Generic mfg.
Trial termination: Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Dec 16, 2012
P3, N=48, Terminated, Sponsor: NCIC Clinical Trials Group
Completed --> Active, not recruiting Completed --> Terminated; Poor accrual
- cixutumumab (IMC A12) / Eli Lilly, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial initiation date, Metastases: Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 13, 2012
P2, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Poor accrual Initiation date: Jan 2010 --> Dec 2010
- goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
New P2 trial: Bipolar Androgen-based Therapy for Prostate Cancer (BAT) (clinicaltrials.gov) - Dec 13, 2012
P2, N=33, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- cixutumumab (IMC A12) / Eli Lilly, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Enrollment closed, Metastases: Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 13, 2012
P2, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2010 --> Dec 2010 Recruiting --> Active, not recruiting
- | goserelin acetate / Generic mfg., dutasteride capsule / Generic mfg.
Enrollment closed: Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation (clinicaltrials.gov) - Dec 11, 2012
P4, N=40, Active, not recruiting, Sponsor: Bay State Clinical Trials, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Trial initiation date, Metastases: R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 11, 2012
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Apr 2008 --> Jul 2009
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Trial completion, Metastases: R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 11, 2012
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2008 --> Jul 2009 Active, not recruiting --> Completed
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial: One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (clinicaltrials.gov) - Dec 4, 2012
P3, N=280, Recruiting, Sponsor: Ferring Pharmaceuticals
- | Visanne (dienogest) / Mochida, Bayer
New P4 trial, Head-to-Head: Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin (clinicaltrials.gov) - Nov 28, 2012
P4, N=63, Not yet recruiting, Sponsor: University of Sao Paulo
- goserelin acetate / Generic mfg., exemestane / Generic mfg.
Trial completion, Metastases: Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 7, 2012
P2, N=0, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Nov 6, 2012
P2, N=29, Recruiting, Sponsor: Washington University School of Medicine
- | abiraterone acetate / Generic mfg.
New P2 trial: Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer (clinicaltrials.gov) - Oct 28, 2012
P2, N=37, Recruiting, Sponsor: Duke University
- || goserelin acetate / Generic mfg., tamoxifen / Generic mfg.
New P3 trial: Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer (clinicaltrials.gov) - Oct 22, 2012
P3, N=220, Recruiting, Sponsor: Fudan University
- || Firmagon (degarelix) / Astellas, Ferring
New P3 trial: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Oct 22, 2012
P3, N=100, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
- prednisone / Generic mfg., mitoxantrone / Generic mfg.
Enrollment change: SWOG S9921: S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer (clinicaltrials.gov) - Oct 2, 2012
P3, N=983, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=1360 --> 983
- goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Trial termination, Monotherapy: Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=110, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=1360 --> 983 Active, not recruiting --> Terminated; low accrual
- docetaxel / Generic mfg.
Trial completion: Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Sep 9, 2012
P1/2, N=23, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- docetaxel / Generic mfg.
Trial initiation date: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=25, Recruiting, Sponsor: University of Kansas
Active, not recruiting --> Completed Initiation date: Sep 2008 --> Aug 2012
- | tamoxifen / Generic mfg.
Enrollment open: GBG54: Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (clinicaltrials.gov) - Aug 27, 2012
P3, N=48, Recruiting, Sponsor: German Breast Group
Initiation date: Sep 2008 --> Aug 2012 Not yet recruiting --> Recruiting
- docetaxel / Generic mfg.
Enrollment open: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=25, Recruiting, Sponsor: University of Kansas
Not yet recruiting --> Recruiting Terminated --> Recruiting
- | triptorelin / Generic mfg.
New P4 trial, Metastases: GREAT: GP Extended Action Triptorelin (clinicaltrials.gov) - Aug 26, 2012
P4, N=21, Completed, Sponsor: Ipsen
- || everolimus / Generic mfg.
New P3 trial: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed: Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer (clinicaltrials.gov) - Aug 23, 2012
P2, N=98, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Recruiting Completed --> Active, not recruiting
- | goserelin acetate / Generic mfg.
New P4 trial: The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis. (clinicaltrials.gov) - Aug 22, 2012
P4, N=120, Recruiting, Sponsor: AZ Jan Palfijn Gent
- | thalidomide / Generic mfg.
Enrollment change: Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer (clinicaltrials.gov) - Aug 12, 2012
P3, N=159, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=101 --> 159
- linsitinib (ASP7487) / Sling Therap
Trial termination, Combination therapy, Metastases: Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2012
P2, N=11, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
N=101 --> 159 Active, not recruiting --> Terminated; PI closed study early, all patients experienced severe toxicities and progressed
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Enrollment open: External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer (clinicaltrials.gov) - Jul 9, 2012
P2/3, N=240, Recruiting, Sponsor: Proton Collaborative Group
Active, not recruiting --> Terminated; PI closed study early, all patients experienced severe toxicities and progressed Not yet recruiting --> Recruiting
- ||| tamoxifen / Generic mfg.
New P3 trial: GBG54: Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (clinicaltrials.gov) - Jul 9, 2012
P3, N=48, Recruiting, Sponsor: German Breast Group
- || New P3 trial: NEST: Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (clinicaltrials.gov) - Jun 17, 2012
P3, N=290, Recruiting, Sponsor: Asan Medical Center
- | orteronel (TAK 700) / Takeda
Enrollment open: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Jun 9, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
New P2/3 trial: External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer (clinicaltrials.gov) - May 20, 2012
P2/3, N=240, Recruiting, Sponsor: Proton Collaborative Group
- docetaxel / Generic mfg.
Enrollment closed, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Apr 25, 2012
P1, N=36, Active, not recruiting, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || goserelin acetate / Generic mfg.
New P3 trial: Gonadotropin-releasing Hormone Agonist Prior to Myomectomy (clinicaltrials.gov) - Apr 16, 2012
P3, N=68, Completed, Sponsor: Mt. Hope Maternity Hospital
- ||||| goserelin acetate / Generic mfg.
Enrollment closed, Metastases: Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer (clinicaltrials.gov) - Apr 3, 2012
P3, N=286, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati, Erivedge (vismodegib) / Roche
Enrollment closed, Surgery, Metastases: Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Mar 26, 2012
P1/2, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Metastases: Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=100, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| goserelin acetate / Generic mfg.
Trial completion: Non-Interventional Study of Zoladex in Endometriosis (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=408, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Women With Breast Cancer (clinicaltrials.gov) - Mar 6, 2012
P3, N=446, Completed, Sponsor: Ludwig-Maximilians - University of Munich
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || orteronel (TAK 700) / Takeda
New P3 trial: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
- New P2 trial, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Feb 8, 2012
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Suprefact (buserelin acetate) / Sanofi
Enrollment open: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Jan 24, 2012
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || goserelin acetate / Generic mfg., cyclophosphamide / Generic mfg.
New P3 trial: Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2012
P3, N=416, Active, not recruiting, Sponsor: King Faisal Specialist Hospital & Research Center
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 17, 2012
P1, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Suprefact (buserelin acetate) / Sanofi
Trial completion, Surgery: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 8, 2012
P3, N=361, Completed, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Firmagon (degarelix) / Astellas, Ferring
Trial termination: A Degarelix Trial in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 19, 2011
P3, N=288, Terminated, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data.
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P2 trial, Combination therapy: EMR 63325-015: Tecemotide (L-BLP25) in Prostate Cancer (clinicaltrials.gov) - Dec 19, 2011
P2, N=48, Recruiting, Sponsor: EMD Serono
- || Suprefact (buserelin acetate) / Sanofi
New P3 trial: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2011
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer (clinicaltrials.gov) - Dec 7, 2011
P3, N=246, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data. Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Surgery: Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer (clinicaltrials.gov) - Nov 24, 2011
P2, N=29, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed